Treatment is being administered over 12 weeks to three groups of participants, each receiving OV101 orally on a different dosing schedule — one, two, or three times a day.
Secondary goals include assessing changes in participants’ behavior over the 12-week treatment period, using the Aberrant Behavior Checklist-Community scale adapted for fragile X.
OV101 is designed to be a selective and potent agonist (activator) of a particular subunit of GABAA receptors to restore tonic inhibition — the process by which the brain correctly identifies excitatory and inhibitory neural signals without being overloaded — and improve quality of life of people with fragile X and Angelman syndrome.
Also expected in 2020 are results of SKY ROCKET, which is evaluating the suitability of behavioral, sleep, and functioning scales in males with fragile X, ages 5 to 30. Investigators at Ovid are planning to use data from this trial to complement some of the goals being explored in ROCKET and as a reference for the benefits offered by standard therapies.
Ovid is also expecting top-line results from the Phase 3 NEPTUNE study (NCT04106557) to become available by mid-2020. This trial is investigating the safety and efficacy of OV101 in children with Angelman.
“We expect new late-stage data from our two lead programs and across multiple indications in 2020,” Jeremy Levin, chairman and CEO of Ovid, said in a press release. “We will report data from the Phase 2 ROCKET signal-finding trial in Fragile X syndrome, a program that has the potential to provide a clinical path forward in this poorly served area.”
“2020 is poised to be a pivotal year for our company and importantly, for the patients and families for which we strive every day to help,” Levin added.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?